Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheïra Beldjord(Inserm), Hervé Dombret(University of London Institute in Paris), Agnès Buzyn(Hôpital Saint-Jacques), Véronique Lhéritier(Hospices Civils de Lyon), Éric Delabesse(Hôpital Necker-Enfants Malades), Hélène Cavé(Hôpital Robert-Debré), Nathalie Grardel(Inserm), Patrice Chevallier(Hotel Dieu Hospital), Norbert Ifrah(Institut National du Cancer), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Vahid Asnafi(Hôpital Necker-Enfants Malades), Marina Lafage(Aix-Marseille Université), Beat Schaefer(University Hospital Zurich), Sylvie Chevret(Saint Louis University Hospital), Oumédaly Reman(University of Bern), Thierry Fest(Inserm), Marie C. Béné(Centre Hospitalier Universitaire de Nantes), Elizabeth Macintyre(Inserm), Xavier Thomas(Hôpital Lyon Sud), Nicolas Boissel(Inserm), Yves Chalandon(University of Geneva), Jean‐Michel Cayuela(Inserm), Jean‐Paul Vernant(Hôpital Saint-Jacques), Marie‐Laure Boulland, Françoise Huguet(Centre Hospitalier Universitaire de Toulouse)
Cited by 327
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k